Executives
-
Galvin RoyPresident, Global Plasma & BC -
Miller Laurie A.SVP, Human Resources
-
Simon, ChristopherPresident & CEO
-
Strong Stewart WPresident, Global Hospital
-
Lingamneni AnilaEVP, Chief Technology Officer
-
Llorens JosepEVP, Global Manufacturing
-
Basil Michelle LEVP and General Counsel
-
Maunsell Farris MaryanneVP, Chief Accounting Officer
-
Darecca JamesEVP, Chief Financial Officer
?
Miller Laurie A.
SVP, Human Resources
Haemonetics Corporation
US, Boston [HQ]
CIK
1881751
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
14,393
Price per Share :
$73.49
Equivalence :
$1,057,741.57
Transaction History
-
F14,393 Shares After TransactionValue : $1,388,780.57$22,482.17Transaction Date : 05/15/24
-
Footnotes
-
-
Footnotes:#1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.#2 This number includes unvested RSUs previously reported, 134 shares acquired by the reporting person on October 31, 2023 under the Issuer's 2007 Employee Stock Purchase Plan (as amended, the "ESPP") and 129 shares acquired by the reporting person on April 30, 2024 under the ESPP.
-
F14,160 Shares After TransactionValue : $1,342,368.00$22,088.40Transaction Date : 05/16/24
-
Footnotes
-
-
Footnotes:#1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.#2 This number includes unvested RSUs previously reported, 134 shares acquired by the reporting person on October 31, 2023 under the Issuer's 2007 Employee Stock Purchase Plan (as amended, the "ESPP") and 129 shares acquired by the reporting person on April 30, 2024 under the ESPP.
-
F14,084 Shares After TransactionValue : $1,348,261.32$7,275.48Transaction Date : 05/17/24
-
Footnotes
-
-
Footnotes:#1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.#2 This number includes unvested RSUs previously reported.#3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.#4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
-
A16,173 Shares After TransactionValue : $n/a$0.0Transaction Date : 05/17/24
-
Footnotes
-
-
Footnotes:#1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.#2 This number includes unvested RSUs previously reported.#3 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.#4 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
-
F17,807 Shares After TransactionValue : $1,362,947.78$18,216.52Transaction Date : 09/17/24
-
Footnotes
-
-
Footnotes:#1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.#2 This number includes unvested RSUs previously reported.